Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iterative mRNA rabies vaccine
- Development stage
- Unknown
- Lead developer
- AIM Vaccine Co.
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The iterative mRNA rabies vaccine is a next-generation prophylactic vaccine developed by Ningbo Rong'an Biological Pharmaceutical, a subsidiary of AIM Vaccine. This vaccine utilizes mRNA technology to instruct host cells to produce the rabies virus glycoprotein (G protein), which then triggers the immune system to generate neutralizing antibodies and cellular immunity against the rabies virus. Part of AIM Vaccine's iterative strategy, this candidate is designed to improve upon traditional Vero cell and human diploid cell-based vaccines by offering potentially higher efficacy and more streamlined manufacturing processes. According to the developer's pipeline, the vaccine has reached the approved stage of development.
- Other names
- mRNA rabies vaccineIterative mRNA Rabies VaccineNingbo Rong'an mRNA rabies vaccine
02
Targets
RABV-G (Rabies virus glycoprotein)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on iterative mRNA rabies vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iterative mRNA rabies vaccine.